PAK4 in Melanoma: Could This Target Extend Immunotherapy’s Reach?
Combining PD-1 blockade with PAK4 inhibitors could boost the number of patients helped by the therapy.
All articles by Caroline Seydel
BELINDA Trial Tests Earlier Use of Tisa-Cel in Aggressive B-Cell Non-Hodgkin Lymphoma
Bumping CAR-T cell therapy earlier in the treatment protocol could reduce toxicity and improve survival for patients with relapsed or refractory disease.
Mass Cytometry for Profiling the Classic Hodgkin Lymphoma Microenvironment
The technique allows researchers to detect various subpopulations of immune cells by simultaneous interrogation of dozens of proteins.
Precision Medicine Transcends Tumor Type
Both DRUP and TAPUR have emphasized the importance of documenting the failures, as well as the successes, of the use of off-label therapies in cancer.
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Biomarker Analysis Paves the Way for Targeted Therapies in Prostate Cancer
Genomic profiling reveals the prevalence of various actionable mutations in advanced prostate cancer.
Fragmentation Pattern of Cell-Free DNA Can Reveal Cancer, Even at Early Stages
Machine learning algorithm detected 7 types of cancer in liquid biopsy and identified tissue of disease origin.
Screening Beyond 5 Years Reduces Risk of Lung Cancer-Specific Mortality by 39%
An Italian trial reported fewer deaths with annual or biennial low-dose CT lung screening—and an active surveillance approach reduced overdiagnosis.
Susceptibility to Radiation-Induced Breast Cancer Following Treatment for Hodgkin Lymphoma
Genetic variants associated with radiation-induced breast cancer include MYC-adjacent oncogene PVT1.
Analysis Highlights Link Between Lymphoma and Glyphosate
EPA panelists, frustrated with the agency’s review process, publish their own analysis implicating the controversial herbicide’s role in non-Hodgkin lymphoma risk.
- Loading...
Loading...
Loading... 
Loading...